Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 18, 2012
Grant Date -
Nov 4, 2010
app pub date -
Nov 11, 2008
filing date -
Apr 7, 2006
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully